Abstract:AIM To compare the pharmacoeconomic characteristics of single-pill amlodipine / valsartan therapy and free combination therapy in Chinese hypertensive patients.METHODS Cost minimization analysis was performed through literature review.The cost was calculated according to the Pharmacy & Medical Impact Model.RESULTS Compared with free combination of amlodipine and valsartan,fixed combination of amlodipine and valsartan totally saved 431 yuan per patient per year.With the increasing use of fixed combination,the expenditure saving gradually increased up to 11.45 million yuan,accounting for 0.67% of the total expenditure.CONCLUSION The cost of fixed combination is lower than that of free combination,so it has a better cost-effectiveness and cost-benefit.

Pharmacoeconomic research of amlodipine and valsartan fixed combination